AbCellera completes pricing of $200 million offering, files final prospectus supplement

AbCellera Biologics Inc. finalized terms for its previously announced public offering, filing a final prospectus supplement on August 13, 2026, following the August 12 pricing announcement. The company is offering 17,435,897 common shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 3,076,926 common shares.¹

The public offering price is $9.75 per share and $9.74999 per pre-funded warrant, for a total of $199,999,993.48. After underwriting discounts and commissions of $11,999,999.61, proceeds to AbCellera before expenses are set at $187,999,993.87.¹ The company estimates net proceeds from the offering will be approximately $187.0 million, excluding any proceeds from warrant exercise.¹

AbCellera intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund continued research, development and clinical advancement of its internal pipeline, including its lead program ABCL635, as well as for working capital and other general corporate purposes.¹

After the offering, the company expects to have 323,905,529 common shares outstanding, assuming none of the pre-funded warrants are exercised.¹ AbCellera's net tangible book value as of June 30, 2026 was $811.7 million, or $2.65 per share, and investors in the new offering will experience immediate dilution of $6.67 per share at the offering price.¹

The financing follows positive Phase 2 data for ABCL635 announced August 10, 2026. The randomized, double-blind, placebo-controlled Phase 2 portion enrolled 92 postmenopausal women experiencing roughly 10 moderate or severe hot flashes daily, and the study met its primary efficacy endpoints with statistically significant reductions in frequency and severity of symptoms at week 4 versus placebo after a single dose.¹

Delivery of the shares and pre-funded warrants is expected on or about August 14, 2026.¹ Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are acting as joint book-running managers for the offering.²